cerns with flammability and toxic effects, and new topical treatments include benzyl alcohol, spinosad, and ivermectin.5-6 All of these topical treatments require thorough washing of the hair after application and can have adverse effects such as irritant and contact dermatitis if left in place; rare toxic effects also has been reported with application. Oral ivermectin and trimethoprim-sulfamethoxazole are parenteral agents that have been reported to be efficacious in widespread or resistant infestations. Nonpesticidal therapies also include fine-tooth combing; topical application of petrolatum jelly, mayonnaise, or olive oil; meticulous manual removal; or shaving of the head.3

We present a challenging clinical case in an immunosuppressed host complicated by our patient’s extensive infestation involving his dreadlocks. Traditional topical therapies were not possible without washing because of concerns for topical allergic or irritant dermatitis, and physical methods such as combing out the nits and cutting the hair were refused by the patient. Oral medications were considered but also refused. The Lice Lifters center provided a program and combined intensive topical, nontoxic treatments at a local center and at home and manual removal of nits. These techniques should be considered when traditional therapies are not possible.

Karolyn A. Wanat, MD
Misha Rosenbach, MD

Author Affiliations: Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia (Wanat, Rosenbach).

Corresponding Author: Misha Rosenbach, MD, Department of Dermatology, University of Pennsylvania, 3600 Spruce St, Philadelphia, PA 19104 (misha.rosenbach@uphs.upenn.edu).


Conflict of Interest Disclosures: None reported.


Pigmented Basal Cell Carcinoma: Uncommon Presentation in Blue-Eyed Patients

While other subtypes of basal cell carcinoma (BCC) primarily affect individuals with light eyes and hair, fair complexion, and an inability to tan, pigmented BCC has a predilection for darker-skinned populations with dark brown eyes.1-3 Commonly mistaken as melanoma because of its often dark and irregular pigmentation, pigmented BCC is marked by its firm consistency, translucence, and occasional surface ulceration.7 We present 2 cases of pigmented basal cell carcinoma in a fair skinned patient with blue eyes.

Report of Cases | Patient 1 (Figure, A) is a 75-year-old woman with type I skin, blue eyes, and a history of BCC. She presented with a new pink-brown papule on the back. A biopsy specimen showed masses of basaloid cells within a fibrocellular stroma. Pigment was found both within the tumor cells and in mela

Discussion | Pigmented BCC has been very well documented in patients with darker eyes and skin; however, the number of cases reported in lighter-skinned individuals, including those with type I skin, is limited.1-2,4-5 Tan et al5 in 2008 proposed that the predilection for African American, Hispanic, and Asian populations could be owing to the ability to tan along with the greater melanogenic capacity of dark-haired patients. In a study by Bart and Schnall1 in 1973, only 10% of patients with pigmented BCC had light brown eyes, while the eyes of the remaining 90% were dark brown. There were no cases reported in other eye colors. Rossiello and colleagues6 in 2006 described a case of pigmented BCC in a 29-year-old white woman. There have been few cases of pigmented BCC reported in white patients with blue eyes, further supporting an association with darker skin and eye color.7 Differentiating pigmented BCC from melanoma or atypical melanocytic nevi is essential; in our case, the diagnosis was determined by characteristic histologic findings of benign proliferation of melanocytes throughout the basaloïd tumor islands and numerous pigment-laden melanophages within the fibrocellular tumor stroma. Despite the fact that only 7% of BCCs are pigmented,6 and they are uncommon in fair-skinned populations, pigmented BCC should be included in the differential diagnosis of atypical pigmented lesions in patients with lighter skin or eyes.

Casey I. Coleman, BS
Lara Wine-Lee, MD, PhD
William D. James, MD

Author Affiliations: Temple University School of Medicine, Philadelphia, Pennsylvania (Coleman); Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia (Wine-Lee, James).

Corresponding Author: William D. James, MD, Department of Dermatology, University of Pennsylvania, 3600 Spruce St, 2 Maloney Bldg, Philadelphia, PA 19104 (William.James@uphs.upenn.edu).

Published Online: June 5, 2013. doi:10.1001/jamadermatol.2013.491
Conflict of Interest Disclosures: None reported.


Figure. Photographs Illustrative of the Present Cases

A, Clinical photograph of patient 1 showing blue eyes and fair complexion. B, Histopathologic specimen from patient 1 showing basaloid proliferation with prominent areas of pigmentation consistent with pigmented basal cell carcinoma (hematoxylin-eosin, original magnification ×200). C, Pigmented plaque on the back of patient 2. D, Histopathologic specimen from patient 2 is consistent with a pigmented basal cell carcinoma (hematoxylin-eosin, original magnification ×200).